Curanex Pharmaceuticals (CURX) Registration Filing summary

Company overview and business model

• Focuses on developing and commercializing innovative botanical drugs for inflammatory diseases, leveraging a proprietary platform for identifying and optimizing plant-based compounds.

• Lead candidate, Phyto-N, targets multiple indications including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, NAFLD, gout, and acne, with all research to date in preclinical stages.

• Business model anticipates revenue from product sales, collaborations, licensing, and research grants, with initial commercialization dependent on regulatory approval.

• Acquired key IP assets and preclinical data from a related party, Duraviva, in exchange for equity and cash.

Financial performance and metrics

• No revenue generated in 2023 or the first nine months of 2024, following a strategic shift from dietary supplements to pharmaceutical R&D.

• Net loss of $224,343 for the nine months ended September 30, 2024, and $19,198 for the year ended December 31, 2023, primarily due to increased operating and IPO-related expenses.

• Cash and cash equivalents totaled $571,447 as of September 30, 2024, with improved liquidity from equity issuance.

• Accumulated deficit of $485,286 as of September 30, 2024; total shareholders' equity increased to $640,522.

Use of proceeds and capital allocation

• Estimated net proceeds of $8 million (at $5.00/share) to be allocated: 25% for FDA-required toxicology and pharmacokinetic studies, 12.6% for manufacturing clinical trial material, 37.7% for Phase I clinical trial in ulcerative colitis, and 24.7% for working capital and general purposes.

• Full business plan through FDA approval and product launch estimated to require over $150 million, with future phases dependent on additional fundraising.